Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect

Alex N. Frickenstein(Oklahoma State University Oklahoma City), Jordan M. Hagood(Oklahoma State University Oklahoma City), Collin Britten(University of Oklahoma), Brandon Abbott(University of Oklahoma), Molly McNally(Oklahoma State University Oklahoma City), Catherine A. Vopat(University of Oklahoma), Eian G. Patterson(University of Oklahoma), William M. MacCuaig(Oklahoma State University Oklahoma City), Ajay N. Jain(Oklahoma City University), Keisha B. Walters(University of Oklahoma), Lacey R. McNally(Oklahoma City University)
Pharmaceutics
April 17, 2021
Cited by 123Open Access
Full Text

Abstract

Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations.


Related Papers

No related papers found

Powered by citation graph analysis